Rajan Sharma
Stock Analyst at Goldman Sachs
(2.87)
# 2,770
Out of 5,000 analysts
169
Total ratings
50.8%
Success rate
2.4%
Average return
Main Sectors:
Stocks Rated by Rajan Sharma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Initiated: Buy | $155 | $118.17 | +31.17% | 1 | Sep 10, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 16,300p | 11,680p | +39.55% | 43 | Sep 9, 2026 | |
| IMTX Immatics | Reiterated: Buy | $12 → $12 | $9.11 | +29.53% | 5 | Aug 18, 2026 | |
| AUTL Autolus Therapeutics | Rated: Buy | $5.7 → $5.8 | $2.03 | +185.71% | 6 | Aug 11, 2026 | |
| GMAB Genmab | Reiterated: Buy | $31 → $373 | $33.04 | +1,028.54% | 5 | Aug 7, 2026 | |
| IMCR Immunocore Holdings | Reiterated: Buy | $73 → $74 | $34.47 | +114.68% | 13 | Aug 6, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 1,890p | 1,801p | +4.97% | 31 | Jul 28, 2026 | |
| VALN Valneva SE | Downgraded: Sell | $7.5 → $4.9 | $6.68 | -26.65% | 5 | Apr 22, 2026 | |
| DBVT DBV Technologies | Reiterated: Sell | $7.25 → $5.81 | $13.44 | -56.77% | 3 | Apr 9, 2026 | |
| EPA: DBV DBV Technologies S.A. | Rated: Sell | €1.30 → €1.01 | €2.36 | -57.17% | 5 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | €25.00 → €18.00 | €22.95 | -21.57% | 8 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $813 → $910 | $1,002.31 | -9.21% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.99 | - | 1 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.66 | - | 5 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $45 | $78.52 | n/a | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €2.85 → €3.30 | €2.90 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $107.39 | n/a | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | CHF 2.00 | CHF 5.12 | n/a | 8 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $111.66 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $47 | $48.63 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $41.81 | n/a | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €90.00 → €100.00 | €158.50 | n/a | 6 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €44.00 | €52.00 | n/a | 7 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $20 | $13.57 | n/a | 2 | May 4, 2022 |
ABIVAX Société Anonyme
Sep 10, 2026
Initiated: Buy
Price Target: $155
Current: $118.17
Upside: +31.17%
AstraZeneca PLC
Sep 9, 2026
Reiterated: Buy
Price Target: 16,300p
Current: 11,680p
Upside: +39.55%
Immatics
Aug 18, 2026
Reiterated: Buy
Price Target: $12 → $12
Current: $9.11
Upside: +29.53%
Autolus Therapeutics
Aug 11, 2026
Rated: Buy
Price Target: $5.7 → $5.8
Current: $2.03
Upside: +185.71%
Genmab
Aug 7, 2026
Reiterated: Buy
Price Target: $31 → $373
Current: $33.04
Upside: +1,028.54%
Immunocore Holdings
Aug 6, 2026
Reiterated: Buy
Price Target: $73 → $74
Current: $34.47
Upside: +114.68%
GSK plc
Jul 28, 2026
Reiterated: Hold
Price Target: 1,890p
Current: 1,801p
Upside: +4.97%
Valneva SE
Apr 22, 2026
Downgraded: Sell
Price Target: $7.5 → $4.9
Current: $6.68
Upside: -26.65%
DBV Technologies
Apr 9, 2026
Reiterated: Sell
Price Target: $7.25 → $5.81
Current: $13.44
Upside: -56.77%
DBV Technologies S.A.
Apr 9, 2026
Rated: Sell
Price Target: €1.30 → €1.01
Current: €2.36
Upside: -57.17%
Apr 9, 2026
Rated: Hold
Price Target: €25.00 → €18.00
Current: €22.95
Upside: -21.57%
Feb 26, 2026
Reiterated: Buy
Price Target: $813 → $910
Current: $1,002.31
Upside: -9.21%
Feb 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.99
Upside: -
Jan 9, 2026
Rated: Hold
Price Target: n/a
Current: $1.66
Upside: -
Jul 30, 2025
Reiterated: Buy
Price Target: $35 → $45
Current: $78.52
Upside: n/a
Mar 21, 2025
Reiterated: Hold
Price Target: €2.85 → €3.30
Current: €2.90
Upside: n/a
Oct 3, 2024
Reiterated: Hold
Price Target: n/a
Current: $107.39
Upside: n/a
Jul 30, 2024
Reiterated: Hold
Price Target: CHF 2.00
Current: CHF 5.12
Upside: n/a
May 30, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $111.66
Upside: n/a
May 30, 2024
Initiated Coverage: Hold
Price Target: $47
Current: $48.63
Upside: n/a
Dec 20, 2023
Reiterated: Buy
Price Target: n/a
Current: $41.81
Upside: n/a
Feb 13, 2023
Reiterated: Hold
Price Target: €90.00 → €100.00
Current: €158.50
Upside: n/a
May 16, 2022
Reiterated: Hold
Price Target: €44.00
Current: €52.00
Upside: n/a
May 4, 2022
Downgraded: Hold
Price Target: $40 → $20
Current: $13.57
Upside: n/a